18+ • For Research & Educational Purposes Only • Not Medical Advice  Disclaimer
Peptide Wiki
MetabolicPhase 3

CagriSema

Fixed-dose combination of cagrilintide (amylin analog) and semaglutide, producing 20.4% weight loss in Phase 3 through complementary satiety pathways

Research Reality Check

Strong SupportGood evidence backs this claim.
ClaimSome people claim CagriSema has clear value for metabolic research.
RealityThere is strong human research, but individual claims still need careful reading.
Bottom LineUse the evidence score, sources, and safety notes before taking any claim seriously.
Why People Believe ThisSimple explanations and user stories can sound more certain than the research is.
Watch Out For
Guaranteed resultsExact protocols presented as provenAnecdotes used as proof
423Discussions
2Citations

Evidence Dossier

87Evidence

Phase 3

Evidence score reflects source depth, citations, and research maturity. It is not a medical recommendation.

2Citations
423Discussions
Start Here

CagriSema at a glance

A fast read for beginners, with evidence strength, route context, safety depth, and community activity surfaced before the deeper sections.

Evidence score87Phase 3 human research
Primary routeSubcutaneous InjectionRoute availability varies by context
Safety depthLimited dataReview safety notes before making assumptions
Community questions423Related discussions and experiences

CagriSema is a fixed-dose combination investigational therapy developed by Novo Nordisk, pairing cagrilintide (a long-acting amylin analog) with semaglutide 2.4mg. Amylin is a peptide hormone co-secreted with insulin from pancreatic beta cells that reduces food intake, slows gastric emptying, and suppresses glucagon - mechanisms that are complementary to but distinct from GLP-1 receptor agonism.

How It Works

The rationale for CagriSema is mechanistic synergy: GLP-1 receptor agonism and amylin receptor agonism act on different brainstem and hypothalamic circuits to reduce appetite. Clinical data from the REDEFINE 1 Phase 3 trial (2024) showed mean body weight loss of 22.7% at 68 weeks - approaching retatrutide's Phase 2 results and substantially exceeding semaglutide alone. Gastrointestinal tolerability was broadly similar to semaglutide monotherapy.

CagriSema remains investigational and has not yet received FDA or EMA approval. Novo Nordisk is pursuing regulatory submission based on the Phase 3 program. Its arrival would represent a meaningful addition to the GLP-1 class, offering semaglutide-level tolerability with tirzepatide-or-better weight loss efficacy.

Key Benefits

Superior weight loss to semaglutide alone (~22.7% in Phase 3)
Complementary satiety mechanisms (GLP-1 + amylin)
Blood sugar control
Cardiovascular risk reduction (anticipated from class effect)